MX2023013515A - Inhibidores de la interaccion de menina-mll. - Google Patents
Inhibidores de la interaccion de menina-mll.Info
- Publication number
- MX2023013515A MX2023013515A MX2023013515A MX2023013515A MX2023013515A MX 2023013515 A MX2023013515 A MX 2023013515A MX 2023013515 A MX2023013515 A MX 2023013515A MX 2023013515 A MX2023013515 A MX 2023013515A MX 2023013515 A MX2023013515 A MX 2023013515A
- Authority
- MX
- Mexico
- Prior art keywords
- menin
- inhibitors
- mll
- interaction
- mll interaction
- Prior art date
Links
- 230000003993 interaction Effects 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 101710169972 Menin Proteins 0.000 abstract 1
- 102100030550 Menin Human genes 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163188704P | 2021-05-14 | 2021-05-14 | |
| PCT/US2022/029271 WO2022241265A1 (en) | 2021-05-14 | 2022-05-13 | Inhibitors of the menin-mll interaction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023013515A true MX2023013515A (es) | 2024-02-29 |
Family
ID=84029448
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023013515A MX2023013515A (es) | 2021-05-14 | 2022-05-13 | Inhibidores de la interaccion de menina-mll. |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11919901B2 (https=) |
| EP (1) | EP4337203A4 (https=) |
| JP (1) | JP2024517945A (https=) |
| KR (1) | KR20240047338A (https=) |
| CN (1) | CN117956992A (https=) |
| AR (1) | AR125866A1 (https=) |
| AU (1) | AU2022274325A1 (https=) |
| BR (1) | BR112023023463A2 (https=) |
| CA (1) | CA3213074A1 (https=) |
| CL (1) | CL2023003327A1 (https=) |
| IL (1) | IL308476A (https=) |
| MX (1) | MX2023013515A (https=) |
| TW (1) | TW202311262A (https=) |
| WO (1) | WO2022241265A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017214367A1 (en) | 2016-06-10 | 2017-12-14 | Vitae Pharmaceuticals, Inc. | Inhibitors of the menin-mll interaction |
| EP4132932A4 (en) | 2020-04-07 | 2024-04-17 | Syndax Pharmaceuticals, Inc. | COMBINATIONS OF MENIN INHIBITORS AND CYP3A4 INHIBITORS AND METHODS OF USE THEREOF |
| IL308476A (en) | 2021-05-14 | 2024-01-01 | Syndax Pharmaceuticals Inc | Inhibitors of the menin-mil interaction |
| AR130379A1 (es) * | 2022-09-02 | 2024-12-04 | Hutchmed Ltd | Compuestos de triazina y usos de los mismos |
| CN120529900A (zh) | 2022-11-24 | 2025-08-22 | 奥莱松基因组股份有限公司 | 用于治疗癌症的LSD1抑制剂和Menin抑制剂的组合 |
| WO2025106901A1 (en) * | 2023-11-17 | 2025-05-22 | Quanta Therapeutics, Inc. | Combination cancer therapies with a kras modulator and an rtk-mapk pathway inhibitor |
| WO2025106905A1 (en) * | 2023-11-17 | 2025-05-22 | Quanta Therapeutics, Inc. | Combination therapies with a kras modulator and an immunomodulator inhibitor |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5820915A (en) | 1996-06-27 | 1998-10-13 | Bioavailability Systems, L.L.C. | Method for the preparation of a first-pass effective citrus-derived substance and product thereof |
| US6124477A (en) | 1996-06-27 | 2000-09-26 | Bioavailability Systems, Llc | Anti-first-pass effect compounds |
| US5990154A (en) | 1997-05-30 | 1999-11-23 | Bioavailability Systems, L.L.C. | Anti-first-pass effect compounds and citrus extract |
| US20040058982A1 (en) | 1999-02-17 | 2004-03-25 | Bioavailability System, Llc | Pharmaceutical compositions |
| US6248776B1 (en) | 1997-08-26 | 2001-06-19 | Bioavailability Systems, L.L.C. | Anti-first-pass effect compounds |
| US6063809A (en) | 1997-08-26 | 2000-05-16 | Bioavailability Systems, Llc | Anti-first-pass effect compounds |
| US5993887A (en) | 1998-06-29 | 1999-11-30 | Bioavailability Systems, L.L.C. | Safe citrus juice and process for preparation |
| WO2004037827A1 (en) | 2000-10-20 | 2004-05-06 | Bioavailability Systems, Llc | Synthesis of spiro ortho esters, spiro ortho carbonates, and intermediates |
| JP2007528423A (ja) | 2004-03-11 | 2007-10-11 | セコイア、ファーマシューティカルズ、インコーポレイテッド | 耐性防止レトロウイルスプロテアーゼ阻害薬 |
| US7378441B2 (en) | 2004-05-07 | 2008-05-27 | Sequoia Pharmaceuticals, Inc. | Resistance-repellent retroviral protease inhibitors |
| US20090281114A1 (en) | 2008-05-08 | 2009-11-12 | Fabre-Kramer Pharmaceuticals, Inc. | Indolylalkyl derivatives of pyrimidinylpiperazine and metabolites thereof for treatment of anxiety, depression, and sexual dysfunction |
| CL2009001152A1 (es) | 2008-05-13 | 2009-10-16 | Array Biopharma Inc | Compuestos derivados de n-(4-(cicloalquilo nitrogenado-1-il)-1h-pirrolo[2,3-b]piridin-3-il)amida, inhibidores de cinasa; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa. |
| MX354412B (es) | 2011-06-10 | 2018-03-05 | Merck Patent Gmbh | Composiciones y metodos para la produccion de compuestos de pirimidina con actividad inhibidora de tirosina cinasa de bruton. |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| WO2014164543A1 (en) | 2013-03-13 | 2014-10-09 | The Regents Of The University Of Michigan | Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof |
| US11596636B2 (en) | 2014-01-14 | 2023-03-07 | The Trustees Of The University Of Pennsylvania | Tailored combinatorial epigenetic therapies for P53 gain-of-function tumors |
| US20170119769A1 (en) | 2014-06-10 | 2017-05-04 | The Trustees Of The University Of Pennsylvania | Scaffolds for inhibitors of menin-mll interactions |
| AU2015301746A1 (en) | 2014-08-13 | 2017-02-16 | Celgene Corporation | Combination therapy for treating cancer |
| CN105732636B (zh) | 2014-12-30 | 2020-04-21 | 广东东阳光药业有限公司 | 杂芳化合物及其在药物中的应用 |
| AU2016378579A1 (en) | 2015-12-22 | 2018-06-14 | Vitae Pharmaceuticals, Inc. | Inhibitors of the menin-MLL interaction |
| US10869868B2 (en) | 2016-01-26 | 2020-12-22 | Memorial Sloan Kettering Cancer Center | Targeting chromatin regulators inhibits leukemogenic gene expression in NPM1 mutant leukemia |
| PH12018501955B1 (en) | 2016-03-16 | 2024-01-24 | Kura Oncology Inc | Bridged bicyclic inhibitors of menin-mll and methods of use |
| ES2990061T3 (es) | 2016-05-10 | 2024-11-28 | C4 Therapeutics Inc | Degronímeros espirocíclicos para la degradación de proteínas diana |
| WO2017214367A1 (en) * | 2016-06-10 | 2017-12-14 | Vitae Pharmaceuticals, Inc. | Inhibitors of the menin-mll interaction |
| AU2017326006B2 (en) | 2016-09-16 | 2021-10-28 | Vitae Pharmaceuticals, LLC. | Inhibitors of the menin-MLL interaction |
| JP7307729B2 (ja) | 2017-12-20 | 2023-07-12 | ヤンセン ファーマシューティカ エヌ．ベー． | メニン－ｍｌｌ相互作用のエキソ－アザスピロ阻害剤 |
| JP7060694B2 (ja) | 2018-01-18 | 2022-04-26 | アレイ バイオファーマ インコーポレイテッド | Ｒｅｔキナーゼ阻害剤としての置換ピロロ［２，３－ｄ］ピリミジン化合物 |
| EP3774731A4 (en) | 2018-03-30 | 2021-11-24 | The Regents Of The University Of Michigan | PIPERIDINE COMPOUNDS AS COVALENT MENINE INHIBITORS |
| KR102779601B1 (ko) * | 2018-08-27 | 2025-03-12 | 스미토모 파마 가부시키가이샤 | 광학 활성인 아자비시클로환 유도체 |
| AU2019337547A1 (en) | 2018-09-13 | 2021-03-18 | Merck Sharp & Dohme Llc | Combination of PD-1 antagonist and LAG3 antagonist for treating non-microsatellite instablity-high/proficient mismatch repair colorectal cancer |
| JP2022503792A (ja) | 2018-09-26 | 2022-01-12 | クラ オンコロジー，インク． | メニン阻害剤を用いた血液悪性腫瘍の処置 |
| SG11202106304RA (en) | 2018-12-31 | 2021-07-29 | Biomea Fusion Llc | Irreversible inhibitors of menin-mll interaction |
| EP4132932A4 (en) | 2020-04-07 | 2024-04-17 | Syndax Pharmaceuticals, Inc. | COMBINATIONS OF MENIN INHIBITORS AND CYP3A4 INHIBITORS AND METHODS OF USE THEREOF |
| IL308476A (en) * | 2021-05-14 | 2024-01-01 | Syndax Pharmaceuticals Inc | Inhibitors of the menin-mil interaction |
| TW202320796A (zh) | 2021-08-11 | 2023-06-01 | 美商拜歐米富士恩股份有限公司 | 用於糖尿病的menin-mll相互作用之共價抑制劑 |
| US20250295661A1 (en) * | 2022-05-09 | 2025-09-25 | Syndax Pharmaceuticals, Inc. | Menin-mll inhibitors for the treatment of cancer |
-
2022
- 2022-05-13 IL IL308476A patent/IL308476A/en unknown
- 2022-05-13 MX MX2023013515A patent/MX2023013515A/es unknown
- 2022-05-13 US US17/744,249 patent/US11919901B2/en active Active
- 2022-05-13 TW TW111118095A patent/TW202311262A/zh unknown
- 2022-05-13 US US18/289,970 patent/US20240400564A1/en active Pending
- 2022-05-13 WO PCT/US2022/029271 patent/WO2022241265A1/en not_active Ceased
- 2022-05-13 KR KR1020237043336A patent/KR20240047338A/ko active Pending
- 2022-05-13 EP EP22808443.0A patent/EP4337203A4/en active Pending
- 2022-05-13 AR ARP220101276A patent/AR125866A1/es unknown
- 2022-05-13 CA CA3213074A patent/CA3213074A1/en active Pending
- 2022-05-13 CN CN202280034670.8A patent/CN117956992A/zh active Pending
- 2022-05-13 AU AU2022274325A patent/AU2022274325A1/en active Pending
- 2022-05-13 BR BR112023023463A patent/BR112023023463A2/pt unknown
- 2022-05-13 JP JP2023569958A patent/JP2024517945A/ja active Pending
-
2023
- 2023-11-08 CL CL2023003327A patent/CL2023003327A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112023023463A2 (pt) | 2024-01-30 |
| IL308476A (en) | 2024-01-01 |
| AR125866A1 (es) | 2023-08-23 |
| CA3213074A1 (en) | 2022-11-17 |
| AU2022274325A1 (en) | 2023-10-05 |
| EP4337203A4 (en) | 2025-04-09 |
| JP2024517945A (ja) | 2024-04-23 |
| US20230021684A1 (en) | 2023-01-26 |
| US20240400564A1 (en) | 2024-12-05 |
| KR20240047338A (ko) | 2024-04-12 |
| CL2023003327A1 (es) | 2024-05-03 |
| US11919901B2 (en) | 2024-03-05 |
| EP4337203A1 (en) | 2024-03-20 |
| TW202311262A (zh) | 2023-03-16 |
| CN117956992A (zh) | 2024-04-30 |
| WO2022241265A1 (en) | 2022-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023013515A (es) | Inhibidores de la interaccion de menina-mll. | |
| ECSP22018571A (es) | Degradadores bifuncionales de brd9 y sus métodos de uso | |
| MX2018015252A (es) | Inhibidores de la interaccion de menina-leucemia de linaje mixto. | |
| MX2023013194A (es) | Compuesto inhibidor de atr que contiene sulfoximina. | |
| MX2025007999A (es) | Conjugados de interleucina-2 (il-2) | |
| MX2020009856A (es) | Rimegepant para trastornos relacionados con el peptido relacionado con el gen para calcitonina (cgrp). | |
| BR112018012707A2 (pt) | inibidores da interação de menin-mll | |
| DOP2011000264A (es) | Derivados de aminotetralina, composiciones farmaceuticas que los contienen y sus usos en terapia | |
| CO2021010493A2 (es) | Compuestos de halo-alilamina y uso de los mismos | |
| CO2022015428A2 (es) | Compuesto de oxofenilarsina deuterada y uso del mismo | |
| AR130602A1 (es) | Inhibidores de tead y métodos de uso de los mismos | |
| AR114418A1 (es) | Compuesto cíclico de metilactama y su utilización farmacéutica | |
| AR128066A1 (es) | Compuesto heterocíclico de pirimidina y método de preparación y uso médico de los mismos | |
| AR127431A1 (es) | Compuestos novedosos | |
| MX2024010104A (es) | Compuesto bicíclico condensado que contiene pirrolinona. | |
| MX2026002475A (es) | Analogos de eteres arilicos como inhibidores de la interaccion menina-mll | |
| AR115883A1 (es) | Composición farmacéutica para el tratamiento de la adicción a sustancias psicoactivas y/o para la prevención de las recaídas a dicha adicción | |
| CL2025001273A1 (es) | Compuesto bicíclico fusionado | |
| MX391405B (es) | Inhibidores de azepano de la interacción menina-mll. | |
| AR133672A1 (es) | Análogos de éter de arilo como inhibidores de la interacción entre menina-mll | |
| CO2020000617A2 (es) | Novedosos compuestos que activan la ruta nrf2 | |
| AR130303A1 (es) | Compuestos de pirazolilsulfonamida y su uso terapéutico | |
| DOP2021000028A (es) | Formulaciones de dendrímeros | |
| AR124975A1 (es) | Compuestos químicos | |
| CO2020012484A2 (es) | Inhibidores de secreción de proteínas basados en triazaciclododecansulfonamida ("tcd") |